G Sampathkumar1, P P Valiyaparambil2, H Kumar1, N Bhavani1, V Nair1, U Menon1, A Menon1, N Abraham1, A Chapla3, N Thomas3. 1. Department of Endocrinology, Amrita Institute of Medical Sciences, Amrita University, Ponnekara P.O, Cochin, 682041, Kerala, India. 2. Department of Endocrinology, Amrita Institute of Medical Sciences, Amrita University, Ponnekara P.O, Cochin, 682041, Kerala, India. pravvp@gmail.com. 3. Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India.
Abstract
PURPOSE: To screen for maturity-onset diabetes of the young (MODY) variants in subjects with an early age of onset and positive family history of diabetes mellitus. METHODS: 60 subjects with onset of diabetes between 3 and 30 years of age and parental history (onset < 35 years) of diabetes were recruited after excluding autoimmune, pancreatic and syndromic forms of diabetes. Detailed pedigree chart and clinical data were recorded. MODY genetic testing (MODY 1-13) was performed and variant classification was done adhering to the ACMG guidelines. RESULTS: Baseline characteristics of subjects were as follows: mean age of onset of diabetes 19.9 ± 7 years, mean duration of diabetes 6.3 ± 6.8 years, BMI 23.3 ± 3 kg/m2 and C-peptide 1.56 ± 1.06 nmol/l. Four out of sixty (6.6%) were positive for variants classifiable as pathogenic/likely pathogenic: one patient with HNF4Ac.691C > T, (p.Arg231Trp), two with HNF 1A c.746C > A(p.Ser249Ter) and c.1340C > T(p.Pro447Leu), and one with ABCC8 c.4544C > T (p.Thr1515Met). MODY 1 and MODY 3 variants were documented in the paediatric age group (< 18 years). CONCLUSION: A genetic diagnosis of MODY could be confirmed in only 6.6% (4/60) of patients clinically classifiable as MODY. This is less than that reported in clinically diagnosed MODY subjects of European descent. Newly published population data and more stringent criteria for assessment of pathogenicity and younger age of onset of type 2 diabetes in Indians could have contributed to the lower genetic confirmation rate. Apart from variants in the classical genes (HNF1A, HNF4A), a likely pathogenic variant in a non-classical gene (ABCC8) was noted in this study.
PURPOSE: To screen for maturity-onset diabetes of the young (MODY) variants in subjects with an early age of onset and positive family history of diabetes mellitus. METHODS: 60 subjects with onset of diabetes between 3 and 30 years of age and parental history (onset < 35 years) of diabetes were recruited after excluding autoimmune, pancreatic and syndromic forms of diabetes. Detailed pedigree chart and clinical data were recorded. MODY genetic testing (MODY 1-13) was performed and variant classification was done adhering to the ACMG guidelines. RESULTS: Baseline characteristics of subjects were as follows: mean age of onset of diabetes 19.9 ± 7 years, mean duration of diabetes 6.3 ± 6.8 years, BMI 23.3 ± 3 kg/m2 and C-peptide 1.56 ± 1.06 nmol/l. Four out of sixty (6.6%) were positive for variants classifiable as pathogenic/likely pathogenic: one patient with HNF4Ac.691C > T, (p.Arg231Trp), two with HNF 1A c.746C > A(p.Ser249Ter) and c.1340C > T(p.Pro447Leu), and one with ABCC8 c.4544C > T (p.Thr1515Met). MODY 1 and MODY 3 variants were documented in the paediatric age group (< 18 years). CONCLUSION: A genetic diagnosis of MODY could be confirmed in only 6.6% (4/60) of patients clinically classifiable as MODY. This is less than that reported in clinically diagnosed MODY subjects of European descent. Newly published population data and more stringent criteria for assessment of pathogenicity and younger age of onset of type 2 diabetes in Indians could have contributed to the lower genetic confirmation rate. Apart from variants in the classical genes (HNF1A, HNF4A), a likely pathogenic variant in a non-classical gene (ABCC8) was noted in this study.
Authors: Maggie Shepherd; Ewan R Pearson; Jane Houghton; Gill Salt; Sian Ellard; Andrew T Hattersley Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: Agata Juszczak; Tamara Pavić; Frano Vučković; Amanda J Bennett; Neha Shah; Edita Pape Medvidović; Christopher J Groves; Mario Šekerija; Kyla Chandler; Carla Burrows; Nataša Rojnić Putarek; Marijana Vučić Lovrenčić; Jadranka Ćuća Knežević; Tim J James; Anna L Gloyn; Gordan Lauc; Mark I McCarthy; Katharine R Owen; Olga Gornik Journal: Diabetes Care Date: 2018-11-19 Impact factor: 19.112
Authors: Anna M Steele; Beverley M Shields; Kirsty J Wensley; Kevin Colclough; Sian Ellard; Andrew T Hattersley Journal: JAMA Date: 2014-01-15 Impact factor: 56.272
Authors: S Ellard; H Lango Allen; E De Franco; S E Flanagan; G Hysenaj; K Colclough; J A L Houghton; M Shepherd; A T Hattersley; M N Weedon; R Caswell Journal: Diabetologia Date: 2013-06-15 Impact factor: 10.122